Close Menu
Home › Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan

Interpace Diagnostics Thyroid Tests Covered In-Network by BCBS of Michigan

Jul 31, 2019
|
staff reporter

NEW YORK – Parsippany, New Jersey-based Interpace Diagnostics announced today that it has signed a contract with Blue Cross Blue Shield of Michigan to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, limiting the insurer's members' out-of-pocket expenses. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

What's Popular?

In Cancer

  1. Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

  2. Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

  3. Sysmex Wins Chinese Approval for Breast Cancer IVD Reagent

  4. Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer

  5. Immunis.AI Targets Late 2020 Prostate Cancer Risk Core Assay Launch

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.